biote Corp. Class A (BTMD)

Biote Corp.'s stock has declined significantly over the past six months. Key events impacting the stock include a voluntary product recall due to potential metal particulate matter, which resulted in inventory charges and additional costs. The company also reported a decline in procedure revenue, following a trend of slowing core pellet procedure volumes and elevated clinic attrition. Biote underwent a commercial team expansion and restructuring, which is expected to increase operating expenses. While dietary supplement revenue grew, overall fourth-quarter revenue decreased, and earnings per share missed analysts' expectations.

Biote Corp. exhibits some demand seasonality in its stock performance. February has historically been the strongest month, while August has tended to be the weakest. Over a full calendar year, the stock has an average annual return of -20.52% and an overall monthly win rate of 40.0%.

Biote Corp. is a healthcare company focused on hormone optimization and therapeutic wellness, utilizing a practice-building model. They train physicians and nurse practitioners in bioidentical hormone replacement pellet therapy, offering the "Biote Method" platform that includes education, training, certification, practice management software, and marketing support. The company also sells Biote-branded dietary supplements and sterile pellet insertion kits, with revenue primarily from hormone pellets and supplements. Biote was founded in 2012 and is based in Irving, Texas.

Biote Corp. is based in Irving, Texas, and has a significant market presence across the United States, with a network of 8,600 medical providers. The company also has an expanding international footprint.

Biote Corp.'s brand reputation has been influenced by its science-based approaches and certification program, but also by operational challenges. The voluntary product recall could negatively affect patient and practitioner trust. Declining procedure volumes and clinic attrition suggest challenges in retaining practitioners and growing the primary service offering. Analysts have a "Hold" consensus rating on the stock, indicating a somewhat neutral to cautious outlook.

Biote Corp. has a diverse ownership structure, with significant institutional and individual insider holdings. Institutions collectively possess 42% of the company's shares, with major shareholders including 325 Capital Llc, Bandera Partners LLC, BlackRock, Inc., and Vanguard Group Inc. Individual insiders own 13.2% of the company's shares, with Gary Steven Donovitz being the largest individual shareholder.